Topical PI3K Inhibitor Formulations for Vascular Malformations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular malformations, such as venous malformations, lack specific targeted therapies and are often invasive, with limited understanding of their pathogenesis, and there is a need for topical delivery of PI3K inhibitors to address these conditions.
Innovation Solution
Development of compounds and formulations that inhibit the PI3K pathway by topical delivery, including specific compounds of formula (I) and topical formulations containing these compounds, which are converted to formula (IV) to inhibit phosphoinositide 3-kinase enzymes, thereby treating vascular malformations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical excision, pulsed laser, or sclerotherapy is used to treat vascular malformations, then treatment effectiveness is achieved, but the treatment becomes invasive with risks of recurrence
Solution Approach 1:
The patent replaces mechanical and physical treatment methods (surgical excision, pulsed laser, sclerotherapy) with a pharmacological approach using topical PI3K inhibitor compounds. This substitution eliminates the need for invasive procedures while providing targeted molecular inhibition of the PI3K/AKT pathway, thereby reducing invasiveness and recurrence risk while maintaining treatment effectiveness
Solution Approach 2:
The patent develops compounds with specific molecular structures (formula I) that can be delivered topically to achieve therapeutic concentrations at the target site. By optimizing the chemical parameters of the inhibitor compounds and their delivery formulation, the treatment achieves effective PI3K inhibition through non-invasive topical application, transforming the treatment paradigm from invasive to non-invasive
2Loss of information
If current classification systems are used for vascular malformations, then patient outcome and histological characterization are considered, but pathogenesis understanding remains obscure
Solution Approach 1:
The patent uses PI3K inhibitor compounds as a molecular intermediary to bridge the gap between observed clinical phenomena and underlying pathogenesis. By targeting the PI3K/AKT pathway, the treatment provides a mechanistic explanation for vascular malformation development and progression, transforming the classification system from purely descriptive to pathogenesis-informed
Solution Approach 2:
The patent shifts the classification and understanding paradigm by identifying molecular pathway activation (PI3K/AKT) as a key parameter in vascular malformation pathogenesis. This molecular parameter change enables a new classification approach that incorporates pathogenic mechanisms rather than just clinical and histological features
3Ease of operation
If topical delivery of PI3K inhibitors is implemented, then non-invasive treatment is achieved, but specific targeted therapies have not been previously developed
Solution Approach 1:
The patent segments the treatment approach into distinct molecular targets (PI3K isoforms) and develops specific inhibitor compounds for each. This segmentation allows for targeted topical formulation development, breaking down the complex challenge of creating topical PI3K inhibitors into manageable molecular entities with defined structures and properties
Solution Approach 2:
The patent optimizes multiple parameters including molecular structure (formula I), lipophilicity, molecular weight, and formulation composition to enable effective topical delivery. By systematically adjusting these parameters, the patent transforms the undeveloped area of topical PI3K inhibitors into a viable treatment modality with optimized compounds and formulations
Data Source
AI summary
The present invention provides compounds and topical formulations including the compounds for the treatment of vascular malformations, wherein the compounds are according to formula (I):wherein subscript m, L1, R1, and L1-R1 are as described herein.